Cabaletta Bio, Inc. (CABA)

Market Cap	100.69M
Revenue (ttm)	n/a
Net Income (ttm)	-104.16M
Shares Out	48.88M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,123,563
Open	2.110
Previous Close	2.090
Day's Range	2.025 - 2.140
52-Week Range	1.760 - 24.850
Beta	2.47
Analysts	Strong Buy
Price Target	26.13 (+1,168.45%)
Earnings Date	Mar 20, 2025

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: CABA
• Website: https://www.cabalettabio.com

Analyst Forecast

According to 8 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $26.13, which is an increase of 1,168.45% from the latest price.

Price Target

$26.13

(1,168.45% upside)

Analyst Consensus: Strong Buy